For the Inventor, By the Inventor

Enter inventor name

Seongnam-si, South Korea

Sung Soo Jun

USPTO Granted Patents = 17 (Patent Applications = 15)

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 64(Granted Patents)

Location History:

Gyeongi-do, KR (2013)
Seongnam, KR (2013)
Seongnam-si, KR (2011 - 2015)
Seongnami-si, KR (2017)
Gyeonggi-do, KR (2011 - 2019)

Company Filing History:

Hanall Biopharma Co., Ltd.

Immunomet Therapeutics Inc.

Korea Research Institute of Chemical Technology

Hanall Pharmaceutical Company, Ltd.

where one patent can have more than one assignee

Years Active: 2011-2019

Loading Chart...

Loading Chart...

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10376480 - Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient (2019-08-13),

2. 9993446 - Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient (2018-06-12),

3. 9655916 - Compositions for external application, containing adenosylcobalamin for improvement of skin diseases (2017-05-23),

4. 9464042 - Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient (2016-10-11),

5. 9416098 - Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient (2016-08-16),

6. 9133110 - Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient (2015-09-15),

7. 9068019 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same (2015-06-30),

8. 8895500 - Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same (2014-11-25),

9. 8754037 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same (2014-06-17),

10. 8722674 - 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same (2014-05-13),

11. 8648111 - N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients (2014-02-11),

12. 8642647 - N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same (2014-02-04),

13. 8642083 - Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors (2014-02-04),

14. 8541474 - N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same (2013-09-24),

15. 8394845 - Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor (2013-03-12),

Title: The Innovative Contributions of Sung Soo Jun

Introduction

Sung Soo Jun is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of pharmaceuticals, holding a total of 17 patents. His work focuses on developing innovative compounds that have the potential to address various health issues.

Latest Patents

One of his latest patents involves a biguanide derivative, which includes a preparation method and a pharmaceutical composition containing this derivative as an active ingredient. This biguanide derivative compound, characterized by N1-N5 substitution, demonstrates remarkable effects on the activation of AMPKα and the inhibition of cancer cell proliferation at low doses. Compared to conventional drugs, this compound may be beneficial in treating conditions such as diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, and cancer.

Career Highlights

Sung Soo Jun has worked with notable companies in the pharmaceutical industry, including Hanall Biopharma Co., Ltd. and Immunomet Therapeutics Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Sung Soo Jun has collaborated with talented individuals such as Sung Wuk Kim and Duck Kim. These partnerships have likely enhanced his research and development efforts.

Conclusion

Sung Soo Jun's innovative work in the field of pharmaceuticals, particularly with his biguanide derivative, showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of various health conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…